BriaCell Therapeutics Corp. BCTXF Archives

FridayMar 29, 2019 11:13 am

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) to Release Early Efficacy Data from Combination Study at AACR Annual Meeting

BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting BriaCell has closed the first tranche of a previously announced non-brokered private placement, raising gross proceeds of C$750,000 BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, will present an analysis of the initial efficacy data compiled during a combination study that pairs Bria-IMT, the company’s lead…

TuesdayMar 26, 2019 10:02 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the update, the first tranche comprised of 7,500,000 common shares, each at a price of C$0.10, for gross proceeds of C$750,000. The closing of the second and final tranche of the offering is scheduled to occur in late March 2019. BriaCell intends to use net proceeds…

FridayMar 22, 2019 10:47 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces Changes to Board of Directors and a Private Placement Offering

Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony will be joining the BriaCell board of directors Both additions have extensive experience in the biopharma industry, bringing expert knowledge in the field of clinical oncology Company recently announced a private placement offering that will generate proceeds for the phase IIa combination clinical trial of Bria-IMT with KEYTRUDA in advanced breast cancer BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, announced several key changes to its board of directors on March 18, 2019, as part of the company’s drive…

ThursdayMar 21, 2019 9:23 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces $2M Non-Brokered Private Placement Offering

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, on Wednesday announced its intention to complete a non-brokered private placement of up to 20,000,000 common shares of the company at a price of C$0.10 each for gross proceeds of up to roughly C$2,000,000. The size of the private placement includes the previously announced C$500,000 equity investment by BriaCell Director and Acting Chairman of the Board, Jamieson Bondarenko. In addition to general corporate purposes, BriaCell plans to use the proceeds from the offering to finance the phase IIa combination study of Bria-IMT(TM) with KEYTRUDA® [by…

MondayMar 18, 2019 11:26 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Achieves Important Milestones in Fight against Advanced Breast Cancer

New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in Paris on March 21-22 Researchers at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, are noting significant advancements in clinical trials of the company’s lead cellular immunotherapy product, Bria-IMT, targeting advanced breast cancer.…

MondayMar 18, 2019 9:55 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints BioPharma Industry Experts to Board of Directors

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced the appointment of Dr. Rebecca Taub, M.D., and Vaughn C. Embro-Pantalony to its board of directors. Dr. Saeid Babaei, Rahoul Sharan and Martin Schmieg have resigned from BriaCell’s board of directors, effective immediately. Since 2016, Taub has served as chief medical officer; executive vice president, R&D; and director of the board for Madrigal Pharmaceuticals (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics. She acted as privately-held Madrigal Pharmaceuticals Inc.’s chief executive officer and director of the board since its inception,…

TuesdayMar 12, 2019 2:44 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Secures Investment to Back Clinical Research

Immuno-oncology-focused biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently secured support for its novel immunotherapy clinical research in the form of an equity investment of C$500,000 by the company’s recently appointed director, Jamieson Bondarenko (http://ibn.fm/yMQfi). A recent article includes a comment from Bondarenko regarding the investment, where he states, “The importance of accelerating this work is evidenced in efficacy data of BriaCell’s Phase I/IIa study of Bria-IMT and safety data of the Bria-IMT KEYTRUDA combination study in advanced breast cancer. There exists a unique opportunity to advance BriaCell’s remarkable achievements on behalf of breast cancer patients, survivors and deceased,…

TuesdayMar 12, 2019 11:36 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Switches to Frozen Immunotherapy Formula to Boost Potency and Facilitate Transport

The company has announced an increase in the potency of its lead immunotherapy candidate, Bria-IMT, through cryopreservation The frozen formula simplifies logistics and makes it possible for the immunotherapy to reach patients across long distances without a compromise in the safety or efficiency of the treatment The same cryopreservation approach will be utilized in the case of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy for advanced breast cancer The use of a novel Bria-IMT frozen formulation is one of the exciting new developments that BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) announced recently. Bria-IMT is the company’s lead immunotherapy candidate. It is…

TuesdayMar 05, 2019 3:14 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Working to Fill Vital Need for Effective, Lasting Breast Cancer Treatments

Through its advancement of Bria-IMT and Bria-OTS, BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is developing cutting-edge treatments to address cancer patient needs. A recent article discussing the company reads, “The imminent clinical use of a novel, frozen formulation of Bria-IMT is another exciting development for BriaCell. The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites, where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen formulation is expected…

MondayMar 04, 2019 10:26 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Receives Equity Investment to Support Novel Immunotherapy Clinical Research

Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile Breast cancer is one of the most commonly diagnosed cancers, with 2.1 million new cases expected in 2018 Global cancer immunotherapy market is projected to be valued at nearly $145 billion by 2022 An equity investment of C$500,000 into BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) by the company’s recently-appointed director, Jamieson Bondarenko (http://ibn.fm/okWzb), underscores the vital importance of BriaCell’s proprietary drug development efforts to millions of cancer patients. BriaCell is…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF